August 21st 2025
TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.
Novel Agent S-1 Has Similar Efficacy to 5-FU in Certain Gastric Cancers
August 10th 2017Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.
Current Pancreatic Cancer Guidelines Miss Targetable Mutations
August 10th 2017Germline mutations in pancreatic cancer susceptibility genes were commonly identified in a group of patients with pancreatic cancer who did not report a significant family history of cancer, according to the results of a single-center study.
Parts of Mediterranean Diet Linked With Reduced Colon Polyp Risk
July 11th 2017Adherence to a Mediterranean diet is negatively associated with advanced colorectal polyps, and the specific portions of the diet that appear to have the most influence include high intake of fish and fruit and low intake of soft drinks.
Right-Sided Metastatic CRC Benefits From Adding SIRT to Chemotherapy
July 10th 2017Patients with colorectal cancer that has metastasized to the liver derive a significant benefit from selective internal radiation therapy (SIRT) combined with chemotherapy if their primary tumor is a right-sided tumor, but not if it is a left-sided primary tumor.
New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer
June 15th 2017In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.
The Growing Challenge of Young Adults With Colorectal Cancer
May 16th 2017In this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.